Publications

Chedgy ECp, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, Ritch E, Struss W, Konomura S, Liew J et al..  2018.  Biallelic tumor suppressor loss and DNA repair defects in de novo small cell prostate cancer.. J Pathol.

Ramnarine VRohan, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M et al..  2018.  The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.. Gigascience.

Beltran H, Wyatt AW, Chedgy E, Donoghue A, Annala M, Warner E, Beja K, Sigouros M, Mo F, Fazli L et al..  2017.  Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.. Clin Cancer Res.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KMun, Angeles A, Johnson F et al..  2017.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.. Cancer Discov. 7(1):54-71.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A et al..  2015.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.. Cell Rep. 12(6):922-36.

Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L et al..  2014.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.. Cancer Res. 74(4):1272-83.

Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH et al..  2012.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.. J Pathol. 227(3):286-97.